Phonphimon Wongthida

Medicine · Health Sciences

24h-index2.4kcitations81works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(53), Virus-based gene therapy research(41), Immunotherapy and Immune Responses(18), Viral Infectious Diseases and Gene Expression in Insects(8), Radiopharmaceutical Chemistry and Applications(7)

Publications81 total

Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
2025Open Access
Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
2024Open Access
Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
2024Open Access
Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
2024Open Access
Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
2023Open Access
Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
2023Open Access
Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
2023Open Access
Supplementary Data from Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
2023Open Access
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
Molecular Cancer Therapeutics·2023· 33 citedOpen Access
Data from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
2023Open Access
Data from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
2023Open Access
Supplementary Figure 3 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
2023Open Access
Supplementary Figure legends from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
2023Open Access
Supplementary Figure 1 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
2023Open Access
Supplementary Figure 2 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
2023Open Access
Supplementary Table 1 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
2023Open Access
Supplementary Figure legends from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
2023Open Access
Supplementary Figure 1 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
2023Open Access
Supplementary Table 1 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
2023Open Access
Supplementary Figure 4 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Richard G. Vile(32), Timothy Kottke(26), Jill Thompson(26), Alan Melcher(18), Laura Evgin(17), Rosa María Díaz(16), José S. Pulido(14), Kevin J. Harrington(13), Amanda L. Huff(13), Christopher B. Driscoll(13), Kevin G. Shim(13), Feorillo Galivo(12), Peter J. Selby(12), Matthew Schuelke(9), Dorin Toader(9), Marc Damelin(9), Timothy B. Lowinger(9), Hardev Pandha(8), Scott D. Collins(8), Kalli C. Catcott(8)